Name: Anti-Human PD1 (Cemiplimab Biosimilar)
Brand: InnoCyto
SKU: 501302
Price: 590 USD
Availability: InStock

Shop Now Contact

Anti-Human PD1 (Cemiplimab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
501301	1 mg	$190
501302	5 mg	$590
501303	20 mg	$1390

Bulk/Custom

Product Details

Clone	Cemiplimab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Anti-Human PD-1 (Cemiplimab Biosimilar)
Isotype	Human IgG4
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human PD1
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Synonyms	CD279
Target Name	PD1, PD-1, PDCD1, CD279, SLEB2
Antibody Type	Recombinant
Research Areas	Immune Checkpoints, Activated T cells, Cancer Immunology, Tregs, Tfh cells, Activated B cells
See All Formats	Clone Cemiplimab

Background Information

Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody engineered to specifically bind the programmed death-1 (PD-1) receptor on T lymphocytes. The molecule has a molecular weight of approximately 146 kilodaltons (kDa) and is produced using recombinant DNA technology in mammalian cell expression systems such as Chinese Hamster Ovary (CHO) cells. It is composed of two identical heavy chains and two identical light chains connected by disulfide bonds, forming the classic Y-shaped structure characteristic of antibodies. Each heavy chain contains one variable (VH) and three constant (CH1–CH3) domains, while each light chain consists of a variable (VL) and a constant (CL) domain.

The antigen-binding specificity of Cemiplimab is determined by its complementarity-determining regions (CDRs) located within the VH and VL domains. These CDRs form a highly complementary surface that enables precise and high-affinity interaction with the PD-1 receptor. By binding to PD-1, Cemiplimab blocks its engagement with the endogenous ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). This interruption prevents ligand-induced signaling that would ordinarily attenuate T-cell activation, cytokine production, and proliferation. In experimental immunological studies, such blockade restores or enhances T-cell effector activity and modifies intracellular signaling cascades involved in adaptive immune regulation.

The Fc region of Cemiplimab, derived from the IgG4 subclass, includes an engineered serine-to-proline (S228P) substitution in the hinge region, stabilizing the molecule and preventing half-antibody exchange. Unlike IgG1 antibodies, IgG4 has minimal affinity for Fc gamma receptors (FcγRs) and complement proteins, which minimizes effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The Fc region also interacts with neonatal Fc receptors (FcRn), extending serum half-life by protecting the antibody from lysosomal degradation. Overall, Cemiplimab exemplifies precision antibody engineering, combining structural stability, selective receptor targeting, and finely tuned immune modulation for mechanistic research applications.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips